Iguratimod as an Alternative Therapy for Resistant Lupus Nephritis
April 1, 2020
An investigational treatment, iguratimod showed positive results in an early clinical study of people with lupus nephritis...
Stories & News
New Awardees Announced by the Lupus Research Program that Advocates Helped Create
April 1, 2020
Thirteen new applications for promising scientific studies were just recommended for funding through the Lupus Research Program...
The U.S. Department of Health and Human Services Accepts Donations of Hydroxychloroquine as Possible Treatments for COVID-19 Patients
March 31, 2020
A statement issued March 29 by the U.S. Department of Health and Human Services (HHS) announced that...
Actions from Pharmaceutical Companies to Preserve Hydroxychloroquine (Plaquenil) Supply
March 30, 2020
The rheumatology community has been in discussions with the U.S. Food and Drug Administration and many pharmaceutical...
DECLARACIÓN DEL 26 DE MARZO: La Alianza para la investigación de Lupus pone en perspectiva la escasez de Plaquenil (hidroxicloroquina) para la comunidad con lupus
26 de marzo de 2020
La Alianza para la investigación de Lupus (LRA), la principal organización de investigación del mundo...
CVS Preserving Plaquenil Supply for Patients Taking It
March 26, 2020
CVS put out the following statement yesterday assuring its clients that the company is protecting a supply...
LRA Sponsors COVID-19 Global Rheumatology Alliance
March 25, 2020
LRA Sponsors COVID-19 Global Rheumatology Alliance
The LRA is proud to be among the sponsors of the COVID-19...
Hidroxicloroquina: fármaco típico para tratar el Lupus a prueba para el COVID-19
19 de marzo de 2020
En diciembre de 2019, se identificó un nuevo virus llamado SARS-COV-2 en Wuhan, China. Se...
Hydroxychloroquine: Common Lupus Drug in Testing for COVID-19
March 19, 2020
In December 2019, a new virus called SARS-COV-2 was identified in Wuhan, China. This virus was found...
Actualización sobre COVID-19: un mensaje del presidente y director ejecutivo de la LRA
18 de marzo de 2020
Estimados amigos:
Su bienestar es la máxima prioridad para todos nosotros en la Alianza para la...
COVID-19 Update: A Message from LRA President & CEO
March 18, 2020
Dear Friends,
Your well-being is the utmost priority for all of us at the Lupus Research Alliance (LRA)....
Preguntas frecuentes sobre la COVID-19: Lo que hay que saber
13 de marzo de 2020
La prioridad de Lupus Research Alliance es la salud de las personas que viven con...